Singular Health Group has advanced its US expansion through the deployment of 3DICOM™ licenses under a key contract with Provider Network Solutions, alongside appointing a new US commercial chief to drive growth.
- 250 3DICOM™ licenses deployed to PNS with 500 more planned in early 2026
- Early clinical feedback exceeds cost-saving targets of 3%-5%, potentially saving US$88M annually
- New US subsidiary established and Paige Taylor appointed as US Chief Commercial Officer
- Ongoing pilot programs and discussions with major US healthcare organizations and federal agencies
- Strong cash position of A$12.2M supports planned national rollout and technical development
Contract Execution and Early Success
Singular Health Group Limited (ASX – SHG) has reported solid progress in the September 2025 quarter, notably advancing the deployment of its 3DICOM™ medical imaging software under a binding contract with Provider Network Solutions (PNS). The initial tranche of 250 licenses was successfully rolled out to PNS’s Primary Care Providers, with an additional 500 licenses scheduled for deployment in the first quarter of 2026. This phased rollout is designed to build a robust data set to validate the solution’s effectiveness in reducing duplicate imaging costs.
Early clinical and technical feedback from PNS has been very positive, surpassing the agreed success metrics of 3% to 5% cost savings. Given PNS’s estimated US$35 per member per month expense on duplicated imaging across 4.2 million members, the solution could translate into annual savings of up to US$88 million. This promising start positions Singular Health well for potential contract expansion within PNS’s network and its partners.
Strategic US Expansion and Leadership
In a strategic move to deepen its US market presence, Singular Health established a wholly owned subsidiary, Singular Health USA LLC, and appointed Paige Taylor as its US Chief Commercial Officer. Based in Austin, Texas, Taylor brings extensive experience in healthcare technology and commercial growth, having held senior roles at notable companies like Medtronic and Perimeter Medical Imaging AI. Her leadership is expected to accelerate adoption of 3DICOM™ within the US healthcare ecosystem, particularly among payers and managed care organizations.
This expansion aligns with the company’s broader ambition for a national rollout in 2026, addressing critical challenges such as imaging duplication and interoperability inefficiencies that burden US health plans and providers.
Broader Commercial and Regulatory Developments
Beyond PNS, Singular Health is actively engaged in pilot programs and contract discussions with several major US healthcare organizations, a leading Puerto Rican health fund, and a prominent US university interested in leveraging 3DICOM™ for imaging aggregation and AI development. The company is also progressing regulatory efforts, including FDA submissions for its online viewer platform, supported by an expanded technical team based in Singapore.
On the domestic front, Singular Health’s 3DICOM™ viewer has been implemented at Australian sites accredited by the Royal Australian and New Zealand College of Radiologists, receiving positive feedback for its usability and performance. The company remains involved in national initiatives to establish a medical imaging data exchange framework, underscoring its commitment to interoperability.
Financial Position and Outlook
Financially, Singular Health closed the quarter with a strong cash balance of A$12.2 million, supporting ongoing operations and planned expansion activities. Operating expenses rose to approximately A$1.7 million, reflecting investments in staff recruitment; including the US commercial leadership; and corporate infrastructure ahead of the anticipated US rollout. The company also secured additional funding through the exercise of unlisted options.
Looking ahead, Singular Health is well-positioned to capitalize on its growing pipeline of contracts and pilot programs, with a clear focus on delivering scalable cost savings and interoperability solutions in the global medical imaging sector.
Bottom Line?
With promising early results and strategic US expansion underway, Singular Health is poised for a pivotal year ahead in transforming medical imaging interoperability.
Questions in the middle?
- Will the deployment of the additional 500 licenses in early 2026 confirm the projected cost savings and trigger contract expansion?
- How soon can Singular Health secure formal contracts with US federal agencies and major healthcare organizations beyond PNS?
- What is the timeline and expected impact of FDA approval for the 3DICOM™ Online Viewer on commercial adoption?